Physician profile
Dedrick K Bowe
NPI 1235481755
$6,845.76
in general payments reported to CMS, 2019-2025
31 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $183 · 2021: $278 · 2022: $1,007 · 2023: $2,003 · 2024: $1,642 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,309 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,285.95 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,039.67 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $916.57 | 2021-2025 | Dupixent |
| Electromed, INC. | $643.22 | 2019-2025 | Smartvest |
| Genzyme Corporation | $568.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.47 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Philips North America LLC | $331.20 | 2019-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $287.92 | 2022-2025 | Verquvo, Dificid, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $285.38 | 2023-2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $162.19 | 2023 | Opsumit, Uptravi |
| Grifols USA, LLC | $145.07 | 2023-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Melinta Therapeutics, LLC | $90.39 | 2024 | Rezzayo, Kimyrsa |
| Inogen, INC. | $84.05 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.98 | 2024-2025 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $63.72 | 2022 | |
| Inspire Medical Systems, INC. | $48.19 | 2023 | Inspire |
| Lexicon Pharmaceuticals, INC. | $43.53 | 2023-2024 | Inpefa |
| Genentech USA, INC. | $38.00 | 2019 | |
| Verona Pharma, INC. | $37.50 | 2025 | Ohtuvayre |
| Kiniksa Pharmaceuticals International, Plc | $32.74 | 2024 | Arcalyst |
| Abbott Laboratories | $27.46 | 2022 | |
| Csl Behring | $22.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.56 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.82 | 2023 | Onpattro |
| Insmed, INC. | $17.48 | 2025 | Brinsupri, Arikayce |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2024 | Eliquis |
| Tela Bio, INC. | $16.50 | 2022 | |
| Kci USA, INC. | $14.89 | 2021 | |
| Ethicon US, LLC | $12.13 | 2021 | |
| Resmed Corp | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dedrick Bowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.